Dimitrios Chondros
2018
Compensation breakdown
| Non-Equity Incentive Plan | $263,789 |
|---|---|
| Option Awards | $500,010 |
| Salary | $440,750 |
| Stock Awards | $500,016 |
| Other | $9,329 |
| Total | $1,713,894 |
Chondros received $500K in stock awards, accounting for 29% of the total pay in 2018.
Chondros also received $263.8K in non-equity incentive plan, $500K in option awards, $440.8K in salary and $9.3K in other compensation.
Rankings
In 2018, Dimitrios Chondros' compensation ranked 6,506th out of 14,244 executives tracked by ExecPay. In other words, Chondros earned more than 54.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,506 out of 14,244 | 54th |
Division Manufacturing | 2,486 out of 5,759 | 57th |
Major group Chemicals And Allied Products | 926 out of 2,122 | 56th |
Industry group Drugs | 778 out of 1,811 | 57th |
Industry Biological Products, Except Diagnostic Substances | 150 out of 339 | 56th |
Pay ratio
| Dimitrios Chondros' Pay | $1,713,894 |
|---|---|
| Median Employee's Pay | $199,899 |
| Pay Ratio | 9to 1 |
In 2018, the annual total compensation of Dimitrios Chondros was $1,713,894.
The annual total compensation of the median employee at Halozyme Therapeutics was $199,899.
The ratio of Dimitrios Chondros' pay to the pay of median employee was therefore 9 to one.
Chondros' colleagues
We found four more compensation records of executives who worked with Dimitrios Chondros at Halozyme Therapeutics in 2018.